Mycophenolat Mofetil Accord (Mycophenolate Mofetil)

Mycophenolate mofetil selectively blocks the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for de novo synthesis of guanosine nucleotides in lymphocytes. By limiting guanosine production, the drug reduces DNA synthesis and proliferation of activated T and B cells, thereby suppressing the immune response that leads to graft rejection and autoimmune inflammation.

The dosage of Mycophenolat Mofetil Accord is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and concomitant therapies. Only a qualified healthcare professional can determine the appropriate regimen; patients should follow the prescriber’s instructions and not adjust the dose on their own.

Mycophenolate mofetil is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women because of a high risk of fetal malformations and miscarriage. It is also not recommended during breastfeeding, as the drug can be excreted in breast milk and may affect the infant. Alternative therapies should be considered for women who are pregnant or planning pregnancy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mycophenolat Mofetil Accord. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mycophenolate mofetil differs from calcineurin inhibitors such as cyclosporine or tacrolimus by targeting nucleotide synthesis rather than calcineurin signaling. This distinct mechanism often results in a different side‑effect profile, with less nephrotoxicity but higher rates of gastrointestinal upset and bone‑marrow suppression. Choice of therapy depends on the transplant protocol, patient tolerance and physician preference.

Mycophenolat Mofetil Accord should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

The medication is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. Doses are typically divided throughout the day to maintain steady blood levels. Patients should swallow the dosage form whole and avoid crushing or chewing unless specifically instructed.

Serious risks include opportunistic infections such as Pneumocystis jirovecii pneumonia, progressive multifocal leukoencephalopathy (PML), severe bone‑marrow suppression leading to aplastic anemia or pancytopenia, and an increased long‑term risk of certain malignancies, especially post‑transplant lymphoproliferative disorders. Prompt medical attention is required if severe infection or unexplained blood count changes occur.

Mycophenolat Mofetil Accord is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate mofetil or any component of the formulation, and patients with severe, uncontrolled infections. Caution is also advised for those with significant renal or hepatic impairment, and it should be avoided in combination with other strong bone‑marrow suppressants unless specifically directed by a specialist.